Jump to content
Invision Community
FORUMS BLOG/NEWS USER BLOGS USER MEDIA ADVERTS   ADD  MANAGE CHAT CLUBS & USER'S PERSONAL FORUMS LINK EXCHANGE
META-99 SEARCH ENGINE             CONTACT US

All Activity

This stream auto-updates     

  1. Yesterday
  2. The “Bispecific Antibody Therapeutics Market, 2019-2030” report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. Key Inclusions · A detailed review of the overall landscape of bispecific antibody therapeutics, including information on drug developers, phase of development (marketed, clinical, and preclinical / discovery) of the pipeline candidates, target antigen, type of antibody format, mechanism of action, target disease indication(s), therapeutic area, broader disease segment, route of administration, mode of administration and patient segment. · A comprehensive list of novel technology platforms that are either currently available or being developed by various firms for the generation of bispecific antibody therapeutics, along with detailed profiles of key technologies. The chapter also includes an insightful competitiveness analysis, featuring a three-dimensional bubble representation that highlights the key technologies that are being used for the development of bispecific antibodies, taking into consideration the early stage (discovery, preclinical, IND and phase I) and late stage (phase II and above) development activity based on the technology (in terms of the number of drugs across different phases of development), number of partnerships established related to the technology and size of the developer company. In addition, it consists of a schematic world map representation, highlighting the geographical locations of technology developers engaged in this domain. · Detailed profiles of marketed and clinical stage (phase II and phase III) bispecific antibody therapeutics. Each profile features an overview of the drug, details of the developer, along with its financial performance, mechanism of action and targets, dosage information, current clinical development status, development process, as well as details on annual sales (wherever available). · Key takeaways from the bispecific antibody therapeutics pipeline, featuring a [A] grid analysis, representing the distribution of the pipeline (on the basis of mechanisms of action of product candidates) across different therapeutic areas and stages of development, a five-dimensional spider-web analysis, highlighting the most popular mechanisms of action based on a number of relevant parameters, including number of bispecific antibodies in early stage (phase I) and late stage of development (phase II and above), number of ongoing clinical trials, target therapeutic areas and the number of companies that are developing these molecules, [C] a two-dimensional scattered plot competitiveness analysis, for the various target combinations for clinical-stage bispecific antibodies and [D] the chapter also includes an insightful summary representation using the logos of different industry stakeholders, highlighting the distribution of companies based on the company size. · An analysis of the big biopharma players engaged in this domain, featuring a heat map based on various parameters, such as number of bispecific antibody therapeutics under development, target antigen, type of antibody format, mechanism of action and target therapeutic area. · An analysis of recent partnerships and collaboration agreements inked in this domain since 2016, covering research collaborations, product and technology licensing agreements, product development and commercialization agreements, manufacturing agreements, mergers / acquisitions, joint ventures, product development agreements and other deals. · A review on the key steps involved and challenges associated with the manufacturing of bispecific antibodies. In addition, it includes a list of contract manufacturing organizations (CMOs) and contract research organizations (CROs). The chapter also highlights the key considerations for bispecific antibody developers while selecting a suitable CRO / CMO. · A clinical trial analysis of ongoing and planned studies related to bispecific antibody therapeutics, taking into consideration a number of relevant parameters, including trial registration year, trial recruitment status, trial phase, trial design, disease indication(s), focus therapeutic area, most active industrial and non-industrial players, and geographical location of the trial. · A review of the key promotional strategies that have been adopted by the developers of the marketed bispecific antibodies, namely Blincyto® and Hemlibra®. It includes a detailed comparison of both the drugs based on the information available on their respective websites, such as patient support offerings, informative downloadable content, and product visibility in scientific conferences. · A discussion on important, industry-specific trends, key market drivers and challenges, under a SWOT framework, featuring a qualitative Harvey ball analysis that highlights the relative impact of each SWOT parameter on the overall market. The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below: Therapeutic Area · Autoimmune Disorders · Eye Disorders · Genetic Disorders · Hematological Malignancies · Infectious Diseases · Inflammatory Disorders · Skin Disorders Mechanism of Action · Cytokines Retargeting / Neutralization · Dual Ligands Blocking · T-cell Retargeting / Activation · Others Target Antigens · CD3 x CD19 · CD30 x CD16A · Factor IXa x Factor X · IL-1α x IL-1β · IL-13 x IL-4 · IL-17A x Albumin · IL-17A x IL-17F · Psl x PcrV · VEGF-A x ANG2 · Others Key Players · Astra Zeneca · Amgen · AbbVie · Affirmed · Affibody · Merck · Roche · Sanofi · Taisho Pharmaceutical Key Geographical Regions · North America · Europe · Asia-Pacific The report features inputs from eminent industry stakeholders, according to whom this relatively novel class of antibody therapeutics is likely to garner significant interest among therapy developers and end users alike. The report includes detailed transcripts of discussions held with the following experts: · Martin Steiner (Chief Executive Officer, Synimmune) · Ludger Große-Hovest (Chief Scientific Officer, Synimmune) · Jane Dancer (Chief Business Officer, F-Star) · Siobhan Pomeroy (Senior Director, Business Development, Cytom X) · Yinjue Wang (Associate Director, Process Development, Innovent Biologics) For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 Gaurav.Chaudhary@rootsanalysis.com
  3. Manufacturing live biotherapeutic products is both technically challenging and financially demanding; as a result, innovator firms are becoming increasingly reliant on contract service providers to access specialized facilities and optimize overall costs. The USD 300 million (by 2030) financial opportunity within the microbiome contract manufacturing market has been analysed across the following segments: Type of Product Manufactured · Active Pharmaceutical Ingredients (APIs) · Finish Drug Formulations (FDFs) Type of Type of Formulation · Solid Formulations · Oral Liquids · Injectables · Others Scale of Operation · Clinical · Commercial Company Size · Small-sized · Mid-sized · Large Key Geographical Regions · North America · Europe · Asia-Pacific and Rest of the World The Live Biotherapeutic Products and Microbiome Contract Manufacturing Market, 2020-2030 report features the following companies, which we identified to be key players in this domain: · Bristol Myers Squibb · GlaxoSmithKline · Incyte · Novartis · Trillium Therapeutics Table of Contents 1. Preface 2. Executive Summary 3. Introduction 4. Market Landscape 5. Company Profiles 6. Regional Capability Analysis 7. Likely Partner Analysis 8. Clinical Trial Analysis 9. Capacity Analysis 10. Demand Analysis 11. Make versus Buy Decision Making Framework 12. Microbiome related initiatives of Big Pharmaceutical Players 13. Market Forecast 14. Conclusion 15. Executive Insights 16. Appendix 1: Tabulated Data 17. Appendix 2: List of Companies and Organizations 18. Appendix 3: List of Probiotic Supplement Contract Manufacturers and Microbial Contract Service Providers For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/microbiome-contract-manufacturing/306.html About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 Gaurav.Chaudhary@rootsanalysis.com
  4. The convenience of subcutaneous route of drug administration and the reformulation of intravenous drugs, reaching patent expiry, for SC delivery has provided an impetus to the development of large volume wearable injectors. In fact, according to the experts in this field, the industry is putting in significant efforts to develop efficient and effective drug-device combinations to deliver large volumes of drugs over a convenient period of time. The USD 2.7 billion and USD 600 million (by 2030) financial opportunity within the large volume wearable injectors market for the delivery of insulin and of non-insulin drugs, respectively, has been analyzed across the following segments: Type of Device · Patch Pump / Injectors · Infusion Pump / Injectors Product Usability · Disposable · Re-usable Therapeutic Area (for non-insulin drugs) · Neurological Disorders · Cardiovascular Disorders · Oncological Disorders · Infectious Disorders Key geographical regions · North America · Europe · Asia Pacific The report Large Volume Wearable Injectors Market (5th Edition), 2020-2030: Focus on Bolus, Basal and Continuous Delivery Devices features the following companies, which we identified to be key players in this domain: · Becton Dickinson · Bespak (subsidiary of Consort Medical) · CeQur · Debiotech · Eli Lilly · Enable Injections · Insulet · Medtronic · PharmaSens · Roche · SOOIL Development · Sonceboz · Sensile Medical (acquired by Gerresheimer) · SteadyMed Therapeutics (acquired by United Therapeutics) · Tandem Diabetes Care · Weibel CDS (acquired by SHL Medical) · West Pharmaceutical Services Table of Contents 1. Preface 2. Executive Summary 3. Introduction 4. Large Volume Wearable Injectors: Current Market Landscape 5. Product Competitiveness Analysis 6. Large Volume Wearable Injectors: Key Players 7. Drug Device Combinations: Tabulated Profiles 8. Partnerships and Collaborations 9. Key Acquisition Targets 10. Patent Analysis 11. Large Volume Wearable Injectors: Likely Drug Candidates 12. Emerging Trends on Social Media 13. Clinical Trial Analysis 14. Case Study: Role of CMOs in Device Development and Manufacturing 15. Regulatory and Reimbursement Landscape for Medical Devices 16. Market Sizing and Opportunity Analysis 17. SWOT Analysis 18. Executive Insights 19. Appendix 1: Tabulated Data 20. Appendix 2: List of Companies and Organizations For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/large-volume-wearable-injectors-market-4th-edition-2018-2030/238.html About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 Gaurav.Chaudhary@rootsanalysis.com
  5. Last week
  6. Cauda equina syndrome (CES) is a serious ailment that must be diagnosed promptly and treated correctly. If your doctor has failed to promptly and correctly diagnose or treat your condition, then you may be entitled to a claim for medical negligence. Patients with this syndrome often complain of severe back pain; the patient’s doctor has a duty of care to check and ensure they do not miss the early warning signs of cauda equina syndrome. In addition to back pain, signs and symptoms of CES may include urinary problems such as retention, incontinence and absent bladder sensation. Other symptoms include sexual dysfunction, pain in one or both legs and bowel weakness. Prompt detection of cauda equina syndrome is crucial as, without emergency surgical attention, the patient may suffer permanent disability in no time. WHY USE MEDICAL NEGLIGENCE DIRECT FOR YOUR CLAIM? Our panel of specialist medical negligence solicitors understand the impact of the cauda equina syndrome and can help you make a claim if you have suffered life-changing consequences. Our thorough but compassionate approach to cauda equina syndrome claims gives each client the confidence that their case is in experienced hands. Our specialist Medical Negligence Experts understand how tough it can be for you to discuss the personal troubles you’ve experienced due to CES negligence. As a result, we provide all the support you need through this difficult process to put you at ease. As experts in this area of medical negligence, we know all that the courts will need to determine negligence, if it gets to trial. The key to a successful cauda equina claim is providing detailed and accurate evidence and ensuring the claim is made within its time limit. We help you achieve success in this regard by: 1. Understanding how your condition developed 2. Demonstrating your relationship with the alleged negligent doctor 3. Collecting your testimony 4. Collecting witness account 5. Compiling medical records Our goal, as always, is to establish the facts of your condition, to make it easy to identify where negligent treatment caused or worsened your cauda equina syndrome. Armed with all the evidence, our dedicated panel of solicitors will move quickly to help you secure the compensation you deserve. While this compensation cannot take your injury away, it will cover the cost of the solutions that can ease the pain you suffer. It can also replace your lost income and provide the financial security that comes with knowing your day-to-day needs will be met. Speak to one of our friendly Cauda Equina Syndrome Solicitors today on 0800 644 4240 or fill our free claim assessment form and we will give you a call back when it is convenient for you.
  7. Hello, How are you today? What tools, method, tutorials do you need now? As your number 1 spammer, fresh results are now available for sale. Mind you, a real phone number for an OTP bypass is available. You can bypass that OTP, registration, app, site, etc. Europe, Asia, the US, Russia phone number is available for app, site verification. Credit card, Bank log, Real Documents: USA, Europe, Asia Passport, Drivers license, National ID. Paid dating site like Match, Zoosk, Muslima, Lovoo, Christianmingle2, Elite single, POF, OkCupid, meet2me, Jdate, etc Credit Union login VPN like Express VPN, Ipvanish, HMA, VyprVPN, 911, Cyber Ghost,t, and many more. Creation of business or personal PayPal to receive and send money. Credit Card, Document to verify your PayPal account. RDP with one month guaranteed. Different country Leads, Companies , business, Ceo - Cfo maillist Tutorials/method: cc to bitcoin, bank log to bitcoin, cc to the gift card, carding, At&t postpaid Verizon, Ach, Wire transfer, spamming, Mobile deposit, credit card top-up, hacking, Bill Pay, etc are all available for sale. 100% Live and legit for serious & ready buyer only. Kindly refer your friends to us to enjoy our services too. What's App ICQ : @A69830 Website : spamprivate.com Regards.
  8. According to industry experts, handheld ultrasound imaging devices are being adopted at a faster pace by different end-users owing to their higher efficiency and wider applicability. Further, these devices have proven to be useful in quarantining patients demonstrating symptoms of pleural wall thickening and lung congestion, a characteristic of pneumonia, as well as observed in patients suffering from the novel coronavirus (COVID-19). The USD 1.1 billion (by 2030) financial opportunity within the Handheld Ultrasound Imaging Devices Market has been analyzed across the following segments: Application Area · Cardiac Scanning · Emergency Medicines · Gynecological / Obstetrics Scanning · Musculoskeletal Scanning · Pulmonary Scanning · Urological Scanning · Vascular Surgery · Other Application Areas Type of Transducer Array · Curved · Endocavity · Linear · Phased · Other Scanners Type of Software · Smartphone Applications · Customized Software End-Users · Ambulatory Surgical Centers · Diagnostic Imaging Centers · Hospitals · Maternity Clinics · Specialty Clinics · Other End-Users Key Geographical Regions · North America · Europe · Asia-Pacific and the Rest of the World For more information, please visit https://www.rootsanalysis.com/reports/view_document/handheld-imaging-devices/319.html The Global Handheld Ultrasound Imaging Devices Market, 2020-2030, report features the following companies, which we identified to be key players in this domain: · Aidmax Medical · Beijing Konted Medical Technology · Biim Ultrasound · BreastIT · Butterfly Network · CJ Medical · Clarius Mobile Health · EchoNous · Fujifilm · GE Healthcare · Guangzhou Top Medical Equipment · Healcerion · Interson Medical Instruments · Philips · Somax Systems · VINNO · WuHan Youkey Bio-Medical Electronics · Yor Labs Table of Contents 1. Preface 2. Executive Summary 3. Introduction 4. Market Landscape 5. Company Profiles 6. Brand Positioning Analysis of Key Players 7. Partnerships and Collaborations 8. Cost Saving Analysis 9. Demand Analysis 10. Market Forecast 11. End-User Specific Opportunity Analysis 12. Case Study: Impact of Coronavirus Outbreak 13. Conclusion 14. Executive Insights 15. Appendix 1: Tabulated Data 16. Appendix 2: List of Companies and Organizations For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/handheld-imaging-devices/319.html About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 Gaurav.Chaudhary@rootsanalysis.com
  9. Roots Analysis has done a detailed study on Gene Therapy Market (3rd Edition), 2019-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities. Key Inclusions · A detailed review of the overall landscape of gene therapies and genome editing therapies, including information on various drug / therapy developer companies, phase of development (marketed, clinical, and preclinical / discovery stage) of pipeline candidates, key therapeutic areas (cardiovascular disorders, muscular disorders, neurological disorders, ocular disorders, oncology and others) and target disease indication(s), information on gene type, type of vector used, type of therapy (ex vivo and in vivo), mechanism of action, type of gene modification (gene augmentation, oncolytic viral therapy and others) and special drug designation (if any). · A discussion on the various types of viral and non-viral vectors, along with information on design, manufacturing requirements, advantages, limitations and applications of currently available gene delivery vectors. · A world map representation, depicting the most active geographies, in terms of the presence of companies engaged in developing gene therapies, and a bull's eye analysis, highlighting the distribution of clinical-stage pipeline candidates by phase of development, type of vector and type of therapy (ex vivo and in vivo). · A discussion on the regulatory landscape related to gene therapies across various geographies, namely North America (the US and Canada), Europe and Asia-Pacific (Australia, China, Japan and South Korea), providing details related to the various challenges associated with obtaining reimbursements for gene therapies. · Detailed profiles of marketed and phase II/III and gene therapies, including a brief history of development, information on current development status, mechanism of action, affiliated technology, strength of patent portfolio, dosage and manufacturing details, along with information on the developer company. · An elaborate discussion on the various commercialization strategies that can be adopted by drug developers for use across different stages of therapy development, namely prior to drug launch, at / during drug launch and post-marketing. · A review of various emerging technologies and therapy development platforms that are being used to design and manufacture gene therapies, featuring detailed profiles of technologies that were / are being used for the development of four or more products / product candidates. · An in-depth analysis of the various patents that have been filed / granted related to gene therapies and genome editing therapies, since 2016. The analysis also highlights the key parameters associated with the patents, including information on patent type (granted patents, patent applications and others), publication year, regional applicability, CPC classification, emerging focus areas, leading industry / non-industry players (in terms of the number of patents filed / granted), and patent valuation. · An analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2014-2019. The analysis also provides information on the key value drivers and deal multiples related to the mergers and acquisitions that we came across. · An analysis of the investments made at various stages of development in companies that are focused in this area, between 2014-2019, including seed financing, venture capital financing, IPOs, secondary offerings, debt financing, grants and other offerings. · An analysis of the big biopharma players engaged in this domain, featuring a heat map based on parameters, such as number of gene therapies under development, funding information, partnership activity and strength of patent portfolio. · A case study on the prevalent and emerging trends related to vector manufacturing, with information on companies offering contract services for manufacturing vectors. The study also includes a detailed discussion on the manufacturing processes associated with various types of vectors. · A discussion on the various operating models adopted by gene therapy developers for supply chain management, highlighting the stakeholders involved, factors affecting the supply of therapeutic products and challenges encountered by developers across the different stages of the gene therapy supply chain. · An analysis of the various factors that are likely to influence the pricing of gene-based therapies, featuring different models / approaches that may be adopted by manufacturers to decide the prices of these therapies. For more information, please visit https://www.rootsanalysis.com/reports/view_document/gene-therapy-market-3rd-edition-2019-2030/268.html The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below: Key therapeutic areas · Autoimmune disorders · Cardiovascular diseases · Genetic disorders · Hematological disorders · Metabolic disorders · Ophthalmic disorders · Oncological disorders · Others Type of vector · Adeno associated virus · Adenovirus · Herpes simplex virus type 1 · Lentivirus · Plasmid DNA · Retrovirus · Vaccinia Virus Type of therapy · Ex vivo · In vivo Type of gene modification · Gene augmentation · Immunotherapy · Oncolytic therapy · Others Route of administration · Intraarticular · Intracerebellar · Intramuscular · Intradermal · Intravenous · Intravitreal · Intravesical · Subretinal · Others Key geographical regions · North America · Europe · Asia-Pacific The report includes detailed transcripts of discussions held with the following experts: · Adam Rogers (CEO, Hemera Biosciences) · Al Hawkins (CEO, Milo Biotechnology) · Buel Dan Rodgers (Founder & CEO, AAVogen) · Cedric Szpirer (Executive & Scientific Director, Delphi Genetics) · Christopher Reinhard (CEO and Chairman, Cardium Therapeutics) · Ryo Kubota (Chairman, President and Chief Executive Officer, Acucela) · Jeffrey Hung (CCO, Vigene Biosciences) · Marco Schmeer (Project Manager) & Tatjana Buchholz (Marketing Manager, PlasmidFactory) · Michael Triplett (CEO, Myonexus Therapeutics, acquired by Sarepta Therapeutics) · Robert Jan Lamers (CEO, Arthrogen) · Tom Wilton (Chief Business Officer, LogicBio Therapeutics) For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/gene-therapy-market-3rd-edition-2019-2030/268.html About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 Gaurav.Chaudhary@rootsanalysis.com
  10. With various target combinations and novel mechanisms of action, bispecific antibodies are presently recognized as a potent class of targeted therapies, with the potential to be used as treatment options for a variety of disease indications. Several pipeline candidates have recently entered mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years. The USD 6.9 billion financial opportunity (by 2030) within the Bispecific Antibody Therapeutics Market has been analyzed across the following segments: Therapeutic Area · Autoimmune Disorders · Eye Disorders · Genetic Disorders · Hematological Malignancies · Infectious Diseases · Inflammatory Disorders · Skin Disorders Mechanism of Action · Cytokines Retargeting / Neutralization · Dual Ligands Blocking · T-cell Retargeting / Activation · Others Target Antigens · CD3 x CD19 · CD30 x CD16A · Factor IXa x Factor X · IL-1α x IL-1β · IL-13 x IL-4 · IL-17A x Albumin · IL-17A x IL-17F · Psl x PcrV · VEGF-A x ANG2 · Others Antibody Formats · Asymmetric · Fragments · Symmetric · Others Key Geographical Regions · North America · Europe · Asia-Pacific For more information, please visit https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html The Bispecific Antibody Therapeutics Market (4th Edition), 2020-2030 report features the following companies, which we identified to be key players in this domain: · Amgen · Ablynx · AbbVie · Affibody · Affimed · Alphamab · AstraZeneca · Avillion · Chugai Pharmaceuticals · Eddingpharm · GSK · Merck · Merus · Roche · Regeneron Pharmaceuticals · Taisho Pharmaceuticals · Zymeworks Table of Contents 1. Preface 2. Executive Summary 3. Introduction 4. Market Overview 5. Bispecific Antibody Therapeutics: Technology Platforms 6. Drug Profiles 7. Key Insights 8. Benchmark Analysis: Big Pharma Players 9. Partnerships and Collaborations 10. Contract Services for Bispecific Antibody Therapeutics 11. Clinical Trial Analysis 12. Case Study: Regulatory Guidelines for Bispecific Antibodies 13. Case Study: Promotional / Marketing Strategies 14. SWOT Analysis 15. Market Forecast and Opportunity Analysis 16. Concluding Remarks 17. Executive Insights 18. Appendix 1: Tabulated Data 19. Appendix 2: List of Companies and Organizations For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 Gaurav.Chaudhary@rootsanalysis.com
  11. Do you know that the online presence of your company is the 50% of your business success? If no, then you have to read an interesting description of marketplace website development. In this article you may find information about what factors affect the price and how it is cheap/exprensive to mainatin this site after launching.
  12. Roots Analysis has done a detailed study on Live Biotherapeutic Products and Microbiome Contract Manufacturing Market, 2020-2030: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities. Key Market Insights · The microbiome therapies pipeline features 260 drugs under evaluation across different phases of development; contract service providers have become an integral part of the supply chain owing to their technical expertise. · Presently, over 25 firms across the globe claim to possess the required know-how and infrastructure to offer contract manufacturing services for live biotherapeutic products and microbiome therapies · The market is fragmented, featuring the presence of established players and mid-sized firms across different global regions, with capabilities to manufacture aerobic and / or anaerobic strains, at varying scales of operation · Most of the installed, global live biotherapeutic contract manufacturing capacity presently belongs to dedicated large and mid-sized CMOs, accounting for over 90% of what is available across various geographies · Future growth of the market is likely to be driven by increased demand for these therapeutics; we expect the service-based revenues to grow at an annualized rate of over 46% in the coming decade · In the long-term, the projected market opportunity is anticipated to be well distributed across different types of formulations, sizes of contract service providers and geographical regions For more information, please visit https://www.rootsanalysis.com/reports/view_document/microbiome-contract-manufacturing/306.html Table of Contents 1. PREFACE 1.1. Scope of the Report 1.2. Research Methodology 1.3. Chapter Outlines 2. EXECUTIVE SUMMARY 3. INTRODUCTION 3.1. Chapter Overview 3.2. Concept of Human Microbiota and Microbiome 3.3. Overview of Gut Flora 3.2.3. Role of Gut Flora in Healthy Individuals 3.2.4. Factors Affecting Human Gut Flora 3.4. The Human Microbiome Project (HMP) 3.5. Overview of Microbiome Therapies 3.5.1. Types of Microbiome Therapies 3.5.1.1. Probiotics 3.5.1.2. Prebiotics 3.5.2. Applications of Microbiome Therapies 3.5.3. Microbiome Therapies Supply Chain 3.6. Microbiome-based Product Manufacturing 3.6.1. Key Steps Involved 3.6.2. Associated Challenges 3.6.3. Role of Contract Manufacturing Organizations (CMOs) 3.6.4. Demand for Contract Manufacturing Services 3.7. Key Considerations for Selecting a Suitable CMO Partner 4. MARKET LANDSCAPE 4.1. Chapter Overview 4.2. CMOs Offering Contract Manufacturing for Microbiome Therapeutics: List of Companies 4.2.1. Analysis by Year of Establishment 4.2.2. Analysis by Company Size 4.2.3. Analysis by Scale of Operation 4.2.4. Analysis by Location of Headquarters 4.2.5. Analysis by Type of Service Offered 4.2.6. Analysis by Type of Product Manufactured 4.2.7. Analysis by Type of Drug Molecule 4.2.8. Analysis by Type of Fermentation Required 4.2.9. Analysis by Type of Formulation 4.2.10. Analysis by Type of Primary Packaging Used 4.2.11. Analysis by Number of Manufacturing Facilities 4.2.12. Analysis by Location of Manufacturing Facilities 4.2.13. Analysis by Type of Regulatory Certifications / Accreditations 4.3. Microbiome Therapeutics In-House Manufacturers: List of Companies 4.3.1. Analysis by Year of Establishment 4.3.2. Analysis by Company Size 4.3.3. Analysis by Scale of Operation 4.3.4. Analysis by Location of Headquarters 4.3.5. Analysis by Location of Manufacturing Facilities 5. COMPANY PROFILES 5.1. Chapter Overview 5.2. CMOs Headquartered in North America 5.2.1. Capsugel 5.2.1.1. Company Overview 5.2.1.2. Microbiome-Related Service Portfolio 5.2.1.3. Facilities Dedicated to Microbiome Manufacturing 5.2.1.4. Recent Developments and Future Outlook 5.2.2. Paragon Bioservices 5.2.2.1. Company Overview 5.2.2.2. Microbiome-Related Service Portfolio 5.2.2.3. Facilities Dedicated to Microbiome Manufacturing 5.2.2.4. Recent Developments and Future Outlook 5.2.3. UAS Labs 5.2.3.1. Company Overview 5.2.3.2. Microbiome-Related Service Portfolio 5.2.3.3. Facilities Dedicated to Microbiome Manufacturing 5.2.3.4. Recent Developments and Future Outlook 5.3. CMOs Headquartered in Europe 5.3.1. Biose 5.3.1.1. Company Overview 5.3.1.2. Microbiome-Related Service Portfolio 5.3.1.3. Facilities Dedicated to Microbiome Manufacturing 5.3.1.4. Recent Developments and Future Outlook 5.3.2. Cobra Biologics 5.3.2.1. Company Overview 5.3.2.2. Financial Information 5.3.2.3. Microbiome-Related Service Portfolio 5.3.2.4. Facilities Dedicated to Microbiome Manufacturing 5.3.2.5. Recent Developments and Future Outlook 5.3.3. Cerbios 5.3.3.1. Company Overview 5.3.3.2. Microbiome-Related Service Portfolio 5.3.3.3. Facilities Dedicated to Microbiome Manufacturing 5.3.3.4. Recent Developments and Future Outlook 5.3.4. Inpac Probiotics 5.3.4.1. Company Overview 5.3.4.2. Microbiome-Related Service Portfolio 5.3.4.3. Facilities Dedicated to Microbiome Manufacturing 5.4. CMOs Headquartered in Asia-Pacific and Rest of the World 5.4.1. BJP Laboratories 5.4.1.1. Company Overview 5.4.1.2. Microbiome-Related Service Portfolio 5.4.1.3. Facilities Dedicated to Microbiome Manufacturing 6. REGIONAL CAPABILITY ANALYSIS 6.1. Chapter Overview 6.2. Key Assumptions and Methodology 6.3. Regional Capability Analysis: Microbiome Contract Manufacturers in North America 6.4. Regional Capability Analysis: Microbiome Contract Manufacturers in Europe 6.5. Regional Capability Analysis: Microbiome Contract Manufacturers in Asia-Pacific and Rest of the World 6.6. Concluding Remarks 7. LIKELY PARTNER ANALYSIS 7.1. Chapter Overview 7.2. Scope and Methodology 7.3. Potential Strategic Partners for Microbiome Contract Manufacturers 7.3.1. Opportunities in North America 7.3.2. Opportunities in Europe and Asia-Pacific 8. CLINICAL TRIAL ANALYSIS 8.1. Chapter Overview 8.2. Scope and Methodology 8.3. Clinical Trial Analysis (Industry Players) 8.3.1. Analysis by Trial Registration Year 8.3.2. Analysis by Trial Phase 8.3.3. Analysis by Trial Recruitment Status 8.3.4. Analysis by Trial Registration Year and Recruitment Status 8.3.5. Analysis by Trial Registration Year and Number of Patients Enrolled 8.3.6. Analysis by Study Design 8.3.7. Analysis by Trial Focus 8.3.8. Analysis by Trial Phase and Type of Intervention Model 8.3.9. Analysis by Sponsor / Collaborator 8.3.10. Analysis by Type of Organization 8.3.11. Popular Therapeutic Areas: Analysis by Number of Clinical Trials and Registration Year 8.3.12. Geographical Analysis by Number of Clinical Trials 8.3.13. Geographical Analysis by Trial Recruitment Status 8.4. Clinical Trial Analysis (Non-Industry Players) 8.4.1. Analysis by Trial Registration Year 8.4.2. Analysis by Trial Phase 8.4.3. Analysis by Trial Recruitment Status 8.4.4. Analysis by Trial Registration Year and Recruitment Status 8.4.5. Analysis by Trial Registration Year and Number of Patients Enrolled 8.4.6. Analysis by Study Design 8.4.7. Analysis by Trial Focus 8.4.8. Analysis by Trial Phase and Type of Intervention Model 8.4.9. Analysis by Sponsor / Collaborator 8.4.10. Analysis by Type of Organization 8.4.11. Popular Therapeutic Areas: Analysis by Number of Clinical Trials and Registration Year 8.4.12. Geographical Analysis by Number of Clinical Trials 8.4.13. Geographical Analysis by Trial Recruitment Status For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/microbiome-contract-manufacturing/306.html About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 Gaurav.Chaudhary@rootsanalysis.com
  13. Hi, I'm a newbie in this forum. Hope everyone's doing fine:) I've been into technical blogging for quite a few years and review programmaing courses to get a better understanding of my niche...also wasn't sure on which topic to introduce myself;) So basically, I came across Scaler Academy as I was browsing through some courses while trying to find answers to someone's query. Recently I stumbled upon this article: https://www.thehindu.com/business/scaler-academy-to-hire-500-instructors-this-year/article32023099.ece My first thoughts were, a great initiative by this platform. They are truly revolutionizing the edtech industry. Especially the reason being, the curriculum taught in colleges are so pathetic, when you graduate you begin to realize that you've just earned a degree not the knowledge that is necessary for industries which leads to increase in unemployment. Also reading their success stories adds credibility to the fact that they are fully invested in a student's journey: https://www.quora.com/What-is-your-review-of-Scaler-Academy https://medium.com/@namanbhalla/my-experience-with-ib-academy-c670df4a3ec6 https://dev.to/scaleracademy What's your Review of this Edtech Firm Scaler Academy? Or have you come across scalable courses like this?
  14. Working out what it costs to provide a service can be a lot easier that working out what to charge. Costs are known easier to define. Adding a margin to the cost means you know how much you make. So what could be wrong ? Understanding what a customer will pay is not so simple and unless you understand that principle you will most likely not be maximising your return. The issue with cost plus pricing is best illustrated when you have staff member join you firm and produces the same work in half the time. The cost is half, so does that mean you should charge less ? Similarly, cost-plus pricing is often used with large projects. In that scenario, if you are adding a margin to the cost, providers with bloated cost structures will, by definition, charge more. Businesses which are more efficient will have lower costs but potentially could and should charge the same or maybe more. If we say that price should be based on value, the difficulty is determining what that value is. We don’t know what a customer is prepared to pay. In trying to determine this, here are some considerations. Understand what your competitors are charging – this is easier for a product sold in a store, more difficult for a service based business. Understand your key differentiators from the customer’s perspective. This is not about what superior technical features you product may have, this is about the key benefit your customer derives through the use of your product of service Understand your customers – set up a research team to review how a selected group of customer use your product or service and how they benefit. This means taking the time to understand where the benefits are. For a smaller business a research team may be too extravagant, but similar results could be achieved through an open meeting and asking the right questions. Consider putting your prices up and then gauge the reaction. Some might complain which gives you the opportunity to present your case or come up with a resolution. High maintenance customers, who are also likely to be price sensitive may leave but that can be a win win – they can become a problem to a competitor! What you are left with is often the loyal customers who see the value in what you do and are prepared to pay for it. From these considerations you should be able to build a picture about why a customer would purchase your product or service over a competitor. Here are some examples of value based pricing at work: A friend of mine purchased a box of 8 party games to use at a party for $30. This solved the problem of how to entertain 60 guests – a real bargain. The box consisted of items such as plastic cups, a ping pong ball, some stick and instructions of how to play the games. The cost of the items and the box would have been less than $2 ! The value is the problem that it solves. Professional services firms now have access to technology which means jobs are less labour intensive. Utilising the technology, jobs can be completed in less time and in some cases minimal labour cost. Many are still able to charge the same price and have more streamlined structures supported by a range of technologies. Software products sold on a subscription basis are all value based. Once they are fully developed and live their incremental cost is minimal, but we have all signed up for them ! We have a problem which might be about organising contacts in our address book so we ask google, and google finds something that can solve the problem. We sign up in anticipation that our current problem will be solved and we are prepared to pay for it. Netflix is a subscription based product that essentially provides convenience. You can watch any movie anytime without having to go anywhere. Gym memberships are similar. We pay for the right to have something even though we may not use it. Do we really have time to watch that many movies or do we never get time to go to the gym. By not using the service there is no direct cost to the provider but consumers see value in convenience and flexibility to access the service anytime or anywhere. Businesses that have been successful in recent times understand the principle behind value based pricing. They do consumer research to establish what consumers value and are able to price accordingly thus maximising their returns. Businesses that still rely on cost based models could be missing out. There is always pressure to reduce costs, but if you can identify where the value lies and structure your pricing model accordingly you will probably find you can improve your bottom line.
  15. Earlier
  16. Van Law Firm is a Personal Injury Law Firm led by Attorney Sandy Van. Whether you’ve been hurt in a casino, a motor vehicle accident, or in a work-related accident in Las Vegas, our team can make a difference in your case.
  17. Hi everyone! My team and I are actively working with casinos/bookies in the European sector. The team consists of several developers that generate traffic from mobile apps. We are ready to sell and lease these applications. Top affiliates have 300%+ ROI with these applications. I can show you what it is and how it works; if you have any questions, please do not hesitate to contact me through Skype: live:.cid.c5e388a144068b10
  18. Hi, everyone! Currently I’m actively working with casino / betting in European countries. I have my own team of developers; we generate traffic from mobile applications and are looking for direct and what’s more important - reliable advertisers on CPA/CPL. Ready to provide all the statistics and other achievements to start our work together as soon as possible. Maybe someone in the comments will suggest a good network to work with. Please specify in your letter: - CPA/CPL and geo rate - advantages of working with this network - statistics - conversion Do not hesitate to contact me through Skype: live:.cid.cdec8dc50ae9c0b6
  19. I am looking for information about both fell optimal cost Hong kong electric vehicles research with $0.02 Monthly bonus Somanya, Ghana
  20. Advocating for the legal rights of people, businesses, and HOAs in Northern California and Nevada, the attorneys at Maddox, Segerblom & Canepa, LLP help clients resolve construction defect disputes and find solutions for business, real estate, and civil law matters. Whether you are the victim of a catastrophic event, an HOA in need of general counsel, or you have a defect in the design, construction, or repair of your home, our team will ensure your legal rights, are protected. Call 775-322-3666. WEBSITE
  21. Nowadays, marketing plays a key role in companies' success. As there is a big competition almost in each field of activity, hence it is necessary to promote your business. In my opinion, each company should go digital and have its own website. The topic of marketplace website development has become very popular for the past few years, 'cause Internet has become an integral part of our lives.
  22. Yes we can pay our taxes with credit cards. We can say that credit cards are an easy way to pay tax, But make sure you understand all the ways it will cost you. It can help you to get an opportunity to earn a reward, earn cash back, points or miles and get to pay off a tax bill, but you will have to remember that credit card payments aren’t free. You have to pay a fee that’s a percentage of your tax payment.
  1. Load more activity
×
×
  • Create New...